Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TNYA
TNYA logo

TNYA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Tenaya Therapeutics Inc (TNYA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.000
1 Day change
17.92%
52 Week Range
2.350
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Tenaya Therapeutics Inc (TNYA) is not a good buy for a beginner investor with a long-term focus at this time. The technical indicators show no strong upward momentum, options data reflects low trading sentiment, and the company's financial performance is weak with declining net income and EPS. Additionally, insider selling has significantly increased, which is a negative signal. Without any positive news or catalysts, this stock does not align with the user's investment goals.

Technical Analysis

The MACD is negative and expanding downward, RSI is neutral at 40.011, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 0.69) with resistance at 0.741. Overall, the technical indicators do not suggest a strong buy signal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate minimal trading sentiment, and the implied volatility is high (154.51), suggesting uncertainty in the stock's future price movements.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
10

Positive Catalysts

  • NULL identified. No recent news or events to drive positive momentum.

Neutral/Negative Catalysts

  • Insider selling has increased by 55373.56% over the last month, which is a strong negative signal. The stock has a 40% chance of declining in the next day, week, and month based on historical patterns.

Financial Performance

In Q4 2025, the company reported no revenue growth (0% YoY), a net income drop of -15.36% YoY, and an EPS decline of -57.14% YoY. Gross margin remains at 0%. The financials indicate poor performance and lack of profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes was provided.

Wall Street analysts forecast TNYA stock price to rise
8 Analyst Rating
Wall Street analysts forecast TNYA stock price to rise
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.848
sliders
Low
2
Averages
9.14
High
40
Current: 0.848
sliders
Low
2
Averages
9.14
High
40
Morgan Stanley
Overweight
downgrade
$5 -> $2
AI Analysis
2026-01-08
Reason
Morgan Stanley
Price Target
$5 -> $2
AI Analysis
2026-01-08
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Tenaya Therapeutics to $2 from $5 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Canaccord
Buy
downgrade
$6 -> $4
2025-12-18
Reason
Canaccord
Price Target
$6 -> $4
2025-12-18
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Tenaya Therapeutics to $4 from $6 and keeps a Buy rating on the shares. The firm two key updates from the company; the lifting of the clinical hold on the MyPEAK-1 trial of TN-201 by the FDA and the first look at interim data from the RIDGE-1 Ph1B clinical trial of TN-401 for PKP2-associated ARVC.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TNYA
Unlock Now

People Also Watch